Neither DMXAA nor SnMP alone affected tumor growth, but their combination significantly reduced tumor burden (Figure 4I), indicating that HO activity may act as a resistance mechanism to type I IFN–driven antitumor responses. The gene discussed is HMOX1; the disease is neoplasm.